by GlobeNewsWire | Aug 4, 2016 | Globe Newswire
EXTON, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) today reported financial results for the second quarter ended June 30, 2016 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m....
by GlobeNewsWire | Aug 1, 2016 | Globe Newswire
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) announced an agreement by AnGes, MG, Vical’s long-time partner and an existing shareholder, to purchase approximately $7.8 million of Vical’s common stock in a private placement. The...
by GlobeNewsWire | Jul 27, 2016 | Globe Newswire
EXTON, Pa., July 27, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that the first two adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)....
by GlobeNewsWire | Jul 19, 2016 | Globe Newswire
BOSTON, July 19, 2016 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today provided an update regarding the Company’s ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma...
by GlobeNewsWire | Jul 15, 2016 | Globe Newswire
BOSTON, July 15, 2016 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding the Company’s ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive...